- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05843032
3D Ultrasound, Specimen Examination by Surgeon, and MRI in Surgical Margin Assessment
May 5, 2023 updated by: Fatemeh Makouei, Rigshospitalet, Denmark
3D Ultrasound in the Assessment of Resection Margins During Surgery for Squamous Cell Carcinoma of the Tongue: a Comparison With Clinical Evaluation, MRI, and Histopathology
In the current protocol, application of 3D ex-vivo ultrasound, MRI, and clinical evaluation (palpation and examination) by the surgeon is proposed to analyze the margin status in tongue squamous cell carcinoma and correlate the results to the histopathology findings.
Study Overview
Status
Not yet recruiting
Intervention / Treatment
Detailed Description
Cancer surgery is the primary treatment in the early stages of tongue squamous cell carcinoma (SCC), and the goal is the complete resection of the tumor with an adequate margin of healthy tissue around to ensure proper cancer removal.
Inadequate margins lead to a high risk of local cancer recurrence and the patient will need re-surgery or adjuvant therapies.
Ex-vivo imaging of the resected surgical specimen has been suggested to provide information for margin assessment and thus improve cancer surgery.
In this manuscript, a protocol to investigate the clinical benefit of three-dimensional (3D) ultrasound imaging of the surgical margins and comparing the results to magnetic resonance imaging (MRI) and the clinical examination of the surgical specimen by surgeon (palpation to inspect the resected tissue) has been designed.
Tumor segmentation and margin measurement (Anterior towards apex of tongue, posterior towards base of tongue, medial towards back of tongue, lateral towards floor of mouth, and profound/deep margins) will be performed by head and neck surgeons on 3D ultrasound images and by two consultant radiologists on MRI of the ex-vivo specimen.
Accuracy of each method will be evaluated by computing the proportion of correctly classified margins (positive, close, and free) by each technique with respect to the gold standard histopathology.
Study Type
Interventional
Enrollment (Anticipated)
27
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Fatemeh Makouei, PhD
- Phone Number: +4550243760
- Email: fatemeh.makouei@regionh.dk
Study Contact Backup
- Name: Tobias Todsen, MD, PhD
- Phone Number: +4535452071
- Email: tobias.todsen@regionh.dk
Study Locations
-
-
Hovedstaden
-
Copenhagen, Hovedstaden, Denmark, 2100
- Rigshospitalet
-
Contact:
- Tobias Todsen, MD, PhD
- Phone Number: +4535452071
- Email: tobias.todsen@regionh.dk
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients with biopsy-proven oral tongue squamous cell carcinoma scheduled for surgical treatment
- T1-T3 staging on cross-sectional imaging
Exclusion Criteria:
- T4 staging
- Unable to understand the verbal or written information
- Prior radiotherapy treatment of oral cavity cancer
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Tongue tumor resection
|
3D ultrasound and MR scanning of the resected tongue tumor will be performed.
The resected surgical specimen will also be examined by the surgeon to assess the margins.
The accuracy of the margin assessment by 3D ultrasound, MRI, and surgeon examination will be evaluated by correlating the results to the final histopathology findings.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Accuracy of the 3D ultrasound and MRI compared to the conventional method in measurements of the surgical margins in the resected tongue SCC specimens.
Time Frame: 2 weeks
|
2 weeks
|
|
Diagnostic accuracy - number of margins correctly classified as free (> 5 mm), close (1- 5 mm) or positive (<1 mm) margin by 3D ultrasound and MRI using histopathology findings as the reference
Time Frame: 2 weeks
|
2 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of cases requiring adjuvant treatments (surgery or chemo/radiotherapy)
Time Frame: 2 weeks
|
2 weeks
|
|
Shrinkage of the surgical specimen due to formalin fixation based on the specimen volume measurements on 3D ultrasound images before and after formalin fixation
Time Frame: 2 weeks
|
2 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Chinn SB, Myers JN. Oral Cavity Carcinoma: Current Management, Controversies, and Future Directions. J Clin Oncol. 2015 Oct 10;33(29):3269-76. doi: 10.1200/JCO.2015.61.2929. Epub 2015 Sep 8.
- de Koning KJ, van Es RJJ, Klijn RJ, Breimer GE, Willem Dankbaar J, Braunius WW, van Cann EM, Dieleman FJ, Rijken JA, Tijink BM, de Bree R, Noorlag R. Application and accuracy of ultrasound-guided resections of tongue cancer. Oral Oncol. 2022 Oct;133:106023. doi: 10.1016/j.oraloncology.2022.106023. Epub 2022 Jul 25.
- Tarabichi O, Bulbul MG, Kanumuri VV, Faquin WC, Juliano AF, Cunnane ME, Varvares MA. Utility of intraoral ultrasound in managing oral tongue squamous cell carcinoma: Systematic review. Laryngoscope. 2019 Mar;129(3):662-670. doi: 10.1002/lary.27403. Epub 2018 Aug 27.
- Klein Nulent TJW, Noorlag R, Van Cann EM, Pameijer FA, Willems SM, Yesuratnam A, Rosenberg AJWP, de Bree R, van Es RJJ. Intraoral ultrasonography to measure tumor thickness of oral cancer: A systematic review and meta-analysis. Oral Oncol. 2018 Feb;77:29-36. doi: 10.1016/j.oraloncology.2017.12.007. Epub 2017 Dec 18.
- Narayana HM, Panda NK, Mann SB, Katariya S, Vasishta RK. Ultrasound versus physical examination in staging carcinoma of the mobile tongue. J Laryngol Otol. 1996 Jan;110(1):43-7. doi: 10.1017/s0022215100132682.
- Makouei F, Ewertsen C, Agander TK, Olesen MV, Pakkenberg B, Todsen T. 3D Ultrasound versus Computed Tomography for Tumor Volume Measurement Compared to Gross Pathology-A Pilot Study on an Animal Model. J Imaging. 2022 Dec 19;8(12):329. doi: 10.3390/jimaging8120329.
- de Koning KJ, Koppes SA, de Bree R, Dankbaar JW, Willems SM, van Es RJJ, Noorlag R. Feasibility study of ultrasound-guided resection of tongue cancer with immediate specimen examination to improve margin control - Comparison with conventional treatment. Oral Oncol. 2021 May;116:105249. doi: 10.1016/j.oraloncology.2021.105249. Epub 2021 Mar 26.
- Schmidt Jensen J, Jakobsen KK, Mirian C, Christensen JT, Schneider K, Nahavandipour A, Wingstrand VL, Wessel I, Tvedskov JF, Frisch T, Christensen A, Specht L, Andersen E, Lelkaitis G, Gronhoj C, von Buchwald C. The Copenhagen Oral Cavity Squamous Cell Carcinoma database: protocol and report on establishing a comprehensive oral cavity cancer database. Clin Epidemiol. 2019 Aug 19;11:733-741. doi: 10.2147/CLEP.S215399. eCollection 2019.
- Pagedar NA. Better Visualization of Oral Cancer Margins-A Struggle of Cancer and Technology. JAMA Otolaryngol Head Neck Surg. 2020 Dec 1;146(12):1156-1157. doi: 10.1001/jamaoto.2020.3262. No abstract available.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
May 15, 2023
Primary Completion (Anticipated)
December 30, 2023
Study Completion (Anticipated)
February 15, 2024
Study Registration Dates
First Submitted
April 24, 2023
First Submitted That Met QC Criteria
April 24, 2023
First Posted (Actual)
May 6, 2023
Study Record Updates
Last Update Posted (Actual)
May 9, 2023
Last Update Submitted That Met QC Criteria
May 5, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 21017915
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Sharing Time Frame
Available for 5 years
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Head and Neck Cancer
-
Robert FerrisAmgenCompletedHead and Neck Cancer | Cancer of Head and Neck | Head Cancer | Neck Cancer | Neoplasms, Head and Neck | Cancer of the Head and Neck | Cancer of Neck | Upper Aerodigestive Tract Neoplasms | Neck Neoplasms | Cancer of the Head | Cancer of the Neck | UADT Neoplasms | Cancer of Head | Head Neoplasms | Head, Neck Neoplasms | Neoplasms, Head and other conditionsUnited States
-
Assiut UniversityRecruitingHead and Neck Cancer | Head and Neck Neoplasms | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and NeckEgypt
-
Mayo ClinicCompletedCancer Head Neck | Cancer Neck | Cancer, HeadUnited States
-
West China HospitalNot yet recruitingHead and Neck Cancer | Malignant Neoplasm | Advanced Head and Neck Carcinoma | Head &Amp; Neck Cancer
-
National Cancer Institute (NCI)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
Radboud University Medical CenterUnknown
-
Fondazione IRCCS Policlinico San Matteo di PaviaNestle Health Science; Akern SrlCompletedHead-neck CancerItaly
-
University of California, San FranciscoCompleted
-
Uppsala UniversityRegion Östergötland; Region Skane; Region Västerbotten; Swedish Cancer Society; S... and other collaboratorsNot yet recruitingHead and Neck Cancer | Head and Neck Cancer Squamous Cell CarcinomaSweden
-
Shenzhen SiBiono GeneTech Co.,LtdUnknownAdvanced Head and Neck CancerChina
Clinical Trials on 3D ultrasound, MRI, resected specimen examination by surgeon
-
University of ZurichUniversity Hospital, Strasbourg, France; University College London Hospitals; University Hospital, Essen and other collaboratorsCompletedNeoplasmsUnited Kingdom, Germany, Switzerland, United States, France, New Zealand
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingProstate Carcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8United States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedStage I Kidney Wilms Tumor | Stage II Kidney Wilms Tumor | Stage III Kidney Wilms TumorUnited States, Canada, Australia, New Zealand, Puerto Rico, Israel, Switzerland
-
Children's Oncology GroupRecruitingBilateral Retinoblastoma | Childhood Intraocular Retinoblastoma | Unilateral Retinoblastoma | Group D Retinoblastoma | Stage I RetinoblastomaUnited States, Australia, Canada
-
Children's Oncology GroupNational Cancer Institute (NCI)RecruitingAcute Myeloid LeukemiaUnited States, Canada, Puerto Rico, Australia